FindTrial
Sign In

AZD7442

DRUG9 trials

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France, National Institute of Allergy and Infectious Diseases (NIAID), AstraZeneca

Conditions

COVID-19Corona Virus DiseaseCorona Virus InfectionCovid19SARS-CoV-2

Phase 1

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19
CompletedNCT04507256
AstraZenecaCOVID-19
Start: 2020-08-18End: 2021-10-19Updated: 2024-10-18
Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants
CompletedNCT05166421
AstraZenecaCorona Virus Disease
Start: 2021-11-30End: 2023-07-19Updated: 2024-11-25
AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics
CompletedNCT05281601
AstraZenecaSARS-CoV-2
Start: 2022-03-21End: 2024-04-16Updated: 2025-04-18

Phase 3

Trial of Treatments for COVID-19 in Hospitalized Adults
CompletedNCT04315948
Institut National de la Santé Et de la Recherche Médicale, FranceCorona Virus Infection
Start: 2020-03-22End: 2023-09-25Updated: 2024-09-19
ACTIV-3: Therapeutics for Inpatients With COVID-19
CompletedNCT04501978
National Institute of Allergy and Infectious Diseases (NIAID)Covid19
Start: 2020-08-04End: 2023-07-14Updated: 2023-08-25
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults
CompletedNCT04625972
AstraZenecaCOVID-19
Start: 2020-12-02End: 2022-07-25Updated: 2023-11-21
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
CompletedNCT04625725
AstraZenecaCOVID-19
Start: 2020-11-21End: 2023-12-08Updated: 2024-12-31
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
CompletedNCT04723394
AstraZenecaCOVID-19
Start: 2021-01-28End: 2022-10-19Updated: 2023-07-05
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
CompletedNCT05780437
National Institute of Allergy and Infectious Diseases (NIAID)COVID-19
Start: 2021-02-10End: 2023-06-09Updated: 2025-02-04

Related Papers

Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve.
2026-03-31
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.
2026-01-16
Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial.
2025-12-07
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19.
2025-10-141 citations
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial
Clinical Microbiology and Infection2025-02-062 citations
P-1960. Safety and Pharmacokinetics of Long-acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442) are Consistent after Repeat Dosing: Results from the PROVENT Substudy
Open Forum Infectious Diseases2025-01-291 citations
P-1904. The Interaction of Serum Biomarkers and Lymphopenia on Pulmonary COVID-19 Illness Progression in Hospitalized Patients
Open Forum Infectious Diseases2025-01-29
The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis.
2024-11-121 citations
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
Journal of Antimicrobial Chemotherapy2024-09-054 citations
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
2024-05-044 citations
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
Clinical Infectious Diseases2024-03-2913 citations
4CPS-096 Use of covid-19 antivirals in patients previously treated with tixagevimab/cilgavimab prophylaxis: experience of an Italian hospital
Section 4: Clinical pharmacy services2024-03-011 citations
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
2024-02-253 citations
Serum AZD7442 (tixagevimab–cilgavimab) concentrations and <i>in vitro</i><scp>IC<sub>50</sub></scp> values predict SARS‐CoV‐2 neutralising antibody titres
Clinical & Translational Immunology2024-01-014 citations
1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study
Open Forum Infectious Diseases2023-11-27
1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
Open Forum Infectious Diseases2023-11-27
529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
Open Forum Infectious Diseases2023-11-27
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
The Journal of Infectious Diseases2023-11-094 citations
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
2023-11-022 citations
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
2023-09-266 citations

27 more papers not shown